Premium
Dilemmas in the compassionate supply of investigational cancer drugs
Author(s) -
Lewis J. R. R.,
Lipworth W.,
Kerridge I.,
Doran E.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12530
Subject(s) - medicine , compassionate use , reimbursement , discretion , government (linguistics) , clinical trial , investigational drugs , government regulation , family medicine , health care , economic growth , law , china , political science , linguistics , philosophy , economics
In Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.